<DOC>
	<DOCNO>NCT01571895</DOCNO>
	<brief_summary>The study phase 2 , multicentre , single arm , pilot study . It design determine DF2156A sufficient activity warrant development . A total twelve ( 12 ) BP patient involve , administer DF2156A orally dose 150 mg twice day maximum 14 day . Recruitment competitive among study site , plan number patient enrol . Competitive recruitment choose increase speed recruitment account unexpected occurrence site negatively impact enrolment rate . The single arm design choose appropriate tool pilot phase 2 study , consider BP rare disease placebo control acceptable . Moreover , spontaneous acute recovery active blistering condition , improvement patient outcome attribute positive effect Investigational Product . Each patient involve study screen period , 14 day treatment , require measurement hospital discharge ( plan day 8+1 treatment ) one assessment occasion day 15+1 , either hospital stay hospital discharge ( out-patient visit ) . An optional post-treatment visit might schedule day 30+3 . The objective clinical trial evaluate whether DF2156A potential improve clinical outcome patient active blister BP warrant development . The safety DF2156A specific clinical setting also evaluate .</brief_summary>
	<brief_title>Pilot Efficacy Safety Study Oral DF2156A Patients With Active Bullous Pemphigoid</brief_title>
	<detailed_description />
	<mesh_term>Pemphigoid , Bullous</mesh_term>
	<criteria>Male female patient age &gt; 50 year . Patients newly diagnose relapse bullous pemphigoid base clinical diagnosis confirm direct immunofluorescence indirect immunofluorescence saltspit skin ( BP180 and/or BP230 ELISA ) . Confirmation laboratory test obtain ideally anyway within one week enrolment . For purpose study , clinical relapse define reappearance clinical symptom patient attain remission last 3 month without immunosuppressive treatment . In patient relapse BP , clinical diagnosis confirm indirect immunofluorescence BP180 and/or BP230 ELISA . Patients mild moderate active blistering disease ( total number blister 1 30 ) whether associate urticarial/eczematous lesion . Patients modify ABSIS score ≤50 Patients free systemic treatment may affect course disease follow offperiod prior enrolment : 1 . 3 week : steroid , dapsone , tetracycline , nicotinamide , 2 . 3 month : azathioprine , mycofenolate mofetil , cyclophosphamide , methotrexate , intravenous immunoglobulin , immunoadsorption , TNF antagonists 3 . 12 month : rituximab , leflunomide Patients free topical treatment topical antibiotic antiseptic 4 day prior enrolment . Patients able comply protocol procedure duration study , include schedule followup visit examination . Patients able provide inform consent . Patients Karnofsky rating score &lt; 40 % . Patients mucosal involvement . Patients moderate severe renal impairment per calculate creatinine clearance ( CLcr ) &lt; 50 mL/min accord CockcroftGault formula ( CockcroftGault , 1976 ) . Patients hepatic dysfunction define increase ALT/AST &gt; 3 x upper limit normal ( ULN ) increase total bilirubin &gt; 3 mg/dL [ &gt; 51.3 μmol/L ] . Patients hypoalbuminemia define serum albumin &lt; 3 g/dL . Patients baseline ( day 0/1 , predose ) QTcF &gt; 470 msec . Patients myocardial infarction 6 month prior enrolment . Patients treatment phenytoin , warfarin , sulphonylurea hypoglycemics ( e.g . tolbutamide , glipizide , glibenclamide/glyburide , glimepiride , nateglinide ) high dose amitriptyline ( &gt; 50 mg/day ) . Patients know hypersensitivity nonsteroidal antiinflammatory drug . Patients use investigational agent within 12 month prior enrolment . Pregnant breast feed woman . Unwillingness use effective contraceptive measure 2 month end study drug administration ( female male ) . Additional Exclusion Criteria Germany : Patients hypokalemia define serum potassium &lt; 3.5 mmol/L . Patients clinically relevant bradycardia ( heart rate &lt; 50 beats/min ) Patients complete leave bundle branch block . Patients history uncontrolled labile hypertension Patients history congestive heart failure . Patients history cardiomyopathy . Patients unstable angina pectoris . Patients personal family history congenital document acquire QT interval prolongation . Patients significant atrial ventricular arrhythmia symptomatic arrhythmia past .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Autoimmune inflammatory blister disorder</keyword>
</DOC>